ASCO Annual Meeting: Hematology

Patients with highly transfusion dependent, relapsed/refractory myelodysplastic syndrome appear to have long-lasting transfusion independence and increased hemoglobin following treatment with imetelstat.

Luspatercept may lead to a paradigm shift in the treatment of patients with lower-risk myelodysplastic syndrome, according to an expert from The University of Texas MD Anderson Cancer Center.

Sustained improvements in leukemia outcomes in low- and middle-income countries are feasible with cross border programs, according to an expert from the University of California, San Diego.

Elotuzumab, lenalidomide, high-dose melphalan, as well as umbilical cord blood–derived natural killer cells and autologous stem cell transplant demonstrated tolerability and improved transplant outcomes for high-risk multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, spoke about the safety profile of standard triplet therapy with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma in the phase 3 SWOG 1211 trial and how results of this trial may be used in future datasets to inform treatment in this setting.

C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, discusses the use of lenalidomide, bortezomib, and dexamethasone with or without elotuzumab for newly diagnosed, high-risk multiple myeloma.

At 2022 ASCO, Paul G. Richardson, MD, reviewed the rationale of the phase 3 DETERMINATION study that set out to determine the benefit of lenalidomide maintenance with or without autologous stem transplantation in newly diagnosed multiple myeloma.

In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.

A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.

Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.

Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.

Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.

The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.

Transplant following lenalidomide, bortezomib, and dexamethasone with lenalidomide maintenance was superior to the treatment course without transplant, according to data at 2022 ASCO.

Elderly frail patients with relapsed/refractory multiple myeloma treated with ixazomib plus daratumumab experienced favorable response rates.

Data from the phase 2 IFM 2018-04 trial support the use of daratumumab, carfilzomib, lenalidomide, and dexamethasone coupled with tandem autologous stem cell transplant in eligible patients with high-risk multiple myeloma.

Induction/consolidation daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed RVd alone when it came to minimal residual disease and progression-free survival in patients with newly diagnosed, transplant-eligible myeloma.

Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.

High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.

Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.

Combining magrolimab with azacitidine led to manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.

At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large B-cell lymphoma.

A subgroup analysis of the phase 3 MAIA trial showed rapid, deep, and durable responses with daratumumab plus lenalidomide and dexamethasone vs standard therapy for newly diagnosed multiple myeloma across patient subgroups.

Amrita Y. Krishnan, MD, spoke about the use of teclistamab vs real-world data in patients with relapsed/refractory multiple myeloma.